Home / Products / Genome-edited Cells / GBP5 Knockout GES-1 Cell Line

GBP5 Knockout GES-1 Cell Line

Cat. No. ARG0241
Product Type:

Genome-edited Cells

Tissue Source:

Stomach

In stock
Request a Quote

Short Description 🔒

The GBP5 Knockout GES-1 Cell Line is a CRISPR/Cas9-edited human gastric epithelial cell line lacking the interferon-inducible GTPase GBP5. Derived from immortalized normal gastric mucosa, GES-1 provides a physiologically relevant model of the gastric barrier. GBP5 functions downstream of interferon-?? and STAT1 to facilitate NLRP3 inflammasome assembly and promote autophagy, positioning it as a key innate immune effector. Knockout of GBP5 impairs caspase-1-mediated maturation of IL-1?? and IL-18 and compromises clearance of intracellular bacteria, making this cell line a powerful system for studying H. pylori infection, gastric inflammation, and early carcinogenesis. It is suitable for IL-1?? ELISA, caspase-1 activity assays, western blotting, gentamicin protection assays, and autophagy flux analysis, supporting mechanistic studies and drug screening in innate immunity.

Product Details
Cell Engineering
Immortalization
Culture Conditions
Quality Control
Disclaimer

Product Details

Product Type:
Genome-edited Cells
Tissue Source:
Stomach
Age:
Fetus (9 months)
Sex of Donor:
Unknown
Size/Quantity:
1 million
Shipping info:
Cryopreserved in vials and shipped on dry ice

Cell Engineering Information

Host Cell:
GES-1
Gene Name:
GBP5
Gene Identifier:
NCBI Gene ID 115362
Gene Species:
Homo sapiens (Human)

Immortalization Information

No immortalization information available.

Culture Conditions

Temperature:
37°C
Atmosphere:
5% CO₂

Quality Control

Mycoplasma testing:
Negative for mycoplasma through PCR analysis
Sterility testing:
Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.
Pathogens:
Cells tested negative for HIV-1, HBV, and HCV.

Disclaimer

Intended Use:
This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.
Disclaimer:
Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.
Usage:
By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use. This product is provided "AS IS".

Description 🔒

The GBP5 Knockout GES-1 Cell Line provides a defined human gastric epithelial model in which CRISPR/Cas9 technology has been used to disrupt the endogenous GBP5 locus, eliminating functional expression of GBP5. As an interferon-inducible GTPase, GBP5 mediates critical steps in innate immune signaling, and its genetic deletion allows researchers to interrogate the precise contributions of GBP5 to inflammasome assembly, cytokine processing, and autophagic responses. This gene-edited cell line retains the epithelial characteristics of the parental GES-1 line, ensuring relevance for studies of gastric mucosal immunity.

Derived from normal human fetal gastric mucosa, GES-1 is a non?transformed, immortalized epithelial cell line that faithfully replicates the structural and functional properties of the gastric surface epithelium. It forms polarized monolayers, maintains barrier integrity, and mounts innate immune responses to Helicobacter pylori. This model is extensively used to study gastric mucosal biology, host?pathogen interactions, and the signaling networks underlying gastric inflammation and carcinogenesis. The GBP5 knockout variant therefore provides a genetically clean background for dissecting interferon?driven defense mechanisms in gastric epithelial cells.

GBP5 functions downstream of interferon??? (IFN-??) and interferon??? (IFN-??) stimulation, where its transcription is driven by STAT1 and IRF1, and can also be modulated by NF-??B. The encoded GTPase directly interacts with NLRP3, the adaptor ASC, and pro?caspase?1 to promote inflammasome assembly, leading to autoproteolytic activation of caspase?1. Active caspase?1 then cleaves the pro?inflammatory cytokines pro?IL?1?? and pro?IL?18 into their mature, secreted forms. Beyond its role in the NLRP3 inflammasome, GBP5 facilitates antibacterial autophagy and cooperates with the related GTPases GBP1 and GBP2 to target intracellular bacteria for lysosomal degradation. Disruption of GBP5 thus uncouples upstream interferon signals from downstream inflammasome and autophagy pathways.

Expression of GBP5 in gastric epithelial cells is critical for mounting an effective innate response against H. pylori. GBP5 facilitates NLRP3 inflammasome assembly and caspase?1?mediated maturation of IL?1?? and IL?18, while promoting autophagy?based elimination of intracellular bacteria. Disruption of GBP5 in GES-1 cells attenuates these processes, resulting in impaired cytokine secretion and reduced bacterial clearance. This phenotype models immune evasion by H. pylori and highlights the role of epithelial GBP5 in gastric homeostasis. The knockout line is a powerful tool for investigating early steps in H. pylori?associated gastric cancer and inflammatory bowel disease.

The GBP5 Knockout GES-1 Cell Line supports western blotting, RT?qPCR, IL?1?? ELISA, caspase?1 activity assays, and immunofluorescence for molecular and functional analysis of inflammasome signaling. The H. pylori gentamicin protection assay quantifies intracellular bacterial survival, and autophagy flux assays combined with flow cytometry assess autophagic clearance. These tools enable mechanistic dissection of GBP5?dependent pathways, screening of compounds targeting the interferon?NLRP3 axis, and validation of therapeutic candidates for gastric inflammation and cancer. For further information, please contact Ascent Research.